<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136184">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01911780</url>
  </required_header>
  <id_info>
    <org_study_id>1348.2</org_study_id>
    <nct_id>NCT01911780</nct_id>
  </id_info>
  <brief_title>Compare Efficacy and Safety of Telmisartan/Hydrochlorothiazide With Telmisartan/Hydrochlorothiazide Plus Amlodipine</brief_title>
  <official_title>An Eight-week Randomised Double-blind Study to Compare the Efficacy and Safety of Telmisartan 80 mg and Amlodipine 5 mg and Hydrochlorothiazide 12.5 mg vs. Telmisartan 80 mg and Hydrochlorothiazide 12.5 mg in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Telmisartan 80 mg and Hydrochlorothiazide 12.5 mg, Followed by a 52 Weeks Extension Study to Assess Long Term Safety of Telmisartan 80 mg and Amlodipine 5 mg and Hydrochlorothiazide 12.5 mg</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-centre, randomised, double-blind, active-controlled, parallel-group
      comparative trial to compare the fixed dose combination (FDC) of telmisartan 80 mg +
      hydrochlorothiazide 12.5 mg and amlodipine 5 mg (T80/A5/H12.5 mg) to telmisartan 80 mg+
      hydrochlorothiazide 12.5 mg (T80/H12.5 mg) in blood pressure lowering effect at week 8, the
      end of the double-blind period in essential hypertensive patients who fail to respond
      adequately to telmisartan 80 mg+ hydrochlorothiazide 12.5 mg.

      Patients are assigned to one of the two groups after a 6-week open-label run-in period
      taking T80/H12.5 mg.

      In addition the long-term safety of telmisartan 80 mg+ amlodipine 5 mg+ hydrochlorothiazide
      12.5 mg will be evaluated in a 52-week extension period.

      In the 52-week open label extension period patients who are assigned to the T80/A5/H12.5 mg
      group continue the T80/A5/H12.5 mg therapy, and patients who are assigned to the T80/ /H12.5
      mg group change to the T80/A5/H12.5 mg therapy.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in mean seated diastolic blood pressure (DBP) at trough after 8 weeks of the double-blind period</measure>
    <time_frame>baseline and week 8</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of patients with DBP&lt;90 mmHg and SBP&lt;140 mmHg as seated blood pressure at trough after 8 weeks of the double-blind period</measure>
    <time_frame>week 8</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of patients with DBP&lt;90 mmHg and SBP&lt;140 mmHg as seated blood pressure at trough after 52weeks of the extension period</measure>
    <time_frame>week 52</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean seated systolic blood pressure (SBP) at trough after 8 weeks of the double-blind period</measure>
    <time_frame>baseline and week 8</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean seated DBP at trough after 52weeks of the extension period</measure>
    <time_frame>baseline and week 52</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean seated SBP at trough after 52weeks of the extension period</measure>
    <time_frame>baseline and week 52</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>telmisartan + HCTZ + amlodipine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>telmisartan 80 mg + hydrochlorothiazide (HCTZ) 12.5 mg fixed dose combination (FDC) and amlodipine 5 mg capsule (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and  hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>telmisartan + HCTZ + placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>telmisartan 80 mg + HCTZ FDC tablet and placebo matching amlodipine 5 mg capsule (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and  hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo matching amlodipine capsule</description>
    <arm_group_label>telmisartan + HCTZ + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telmisartan + HCTZ</intervention_name>
    <description>FDC tablet</description>
    <arm_group_label>telmisartan + HCTZ + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telmisartan + HCTZ</intervention_name>
    <description>FDC tablet</description>
    <arm_group_label>telmisartan + HCTZ + amlodipine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amlodipine</intervention_name>
    <description>capsule</description>
    <arm_group_label>telmisartan + HCTZ + amlodipine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Essential hypertensive patients who have already taking 2 or 3 antihypertensive drugs
             and mean seated diastolic blood pressure (DBP) must be &gt;=90 and &lt;=114 mmHg and mean
             seated systolic blood pressure (SBP) must be =&lt;200 mmHg

          2. Able to stop all current antihypertensive drugs (other than study medication) from
             Visit 1b through the end of the trial without risk to the patient based on the
             investigator's opinion

          3. Age 20 years or older

        Exclusion criteria:

          1. Patients with known or suspected secondary hypertension

          2. Patients with clinically relevant cardiac arrhythmia

          3. Congestive heart failure with New York Heart Association (NYHA) functional class
             III-IV

          4. Patients with recent cardiovascular events

          5. Patients with recent stroke events

          6. Patients with a history of sudden deterioration of renal function with angiotensin II
             receptor blockers or angiotensin converting enzyme inhibitors; or patients with
             post-renal transplant or post-nephrectomy

          7. Patients with hepatic and/or renal dysfunction

          8. Pre-menopausal women who are nursing or pregnant
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1348.2.020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chiyoda-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.2.008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chuo-ku, Fukuoka, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.2.018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chuo-ku,Kobe, Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.2.013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chuo-ku,Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.2.021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chuo-ku,Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.2.006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chuo-ku,Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.2.012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hirakata, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.2.011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kasaoka, Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.2.001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kawasaki, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.2.019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kita-ku, Osaka-shi, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.2.014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiyota-ku, Sapporo-shi, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.2.002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kumamoto, Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.2.007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nakano-ku,Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.2.009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nishi-ku, Fukuoka, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.2.005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Takatsuki, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.2.016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Uji, Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.2.010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yoshikawa, Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>July 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Benzoates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
